Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395243 | 0.91 | P4HTM (0.47) | MAPK1P4HTMKDM4EL3MBTL1 | |
| SCHEMBL11956666 | 0.82 | MAPK1 (0.47) | MAPK1P4HTMMEN1KMT2AAHR | |
| SCHEMBL2398113 | 0.81 | P4HTM (0.45) | MAPK1P4HTMMEN1KMT2AAHR | |
| SCHEMBL2394694 | 0.76 | MAPKAPK2 (0.44) | MAPK1P4HTMMEN1KMT2AMAPT | |
| SCHEMBL2392818 | 0.75 | MAPK1 (0.48) | MAPK1P4HTMMEN1KMT2AKDM4E | |
| SCHEMBL11956667 | 0.74 | P4HTM (0.53) | P4HTMMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2397298 | 0.72 | MEN1 (0.46) | MAPK1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL2392565 | 0.69 | MAPK1 (0.48) | MAPK1P4HTMMEN1KMT2AKDM4E | |
| SCHEMBL2396649 | 0.68 | SMN1; SMN2 (0.47) | MAPK1P4HTMMEN1KMT2AKDM4E | |
| SCHEMBL9120996 | 0.68 | RARA (0.61) | MAPK1P4HTMMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2189443-B1 | TRICYCLIC AMIDE COMPOUND | RES FOUND ITSUU LAB (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-8232300-B2 | Tricyclic amide compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2189443-A1 | TRICYCLIC AMIDE COMPOUND | Research Foundation Itsuu Laboratory (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RXRA, RXRB, RXRG | MAPK1 3796/4885P4HTM 1693/4885MEN1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.